Various dual/triple agonists for glucagon-like peptide-1 receptor (GLP-1R), which also target the gastric inhibitory peptide receptor and glucagon receptor, have recently been explored to increase treatment efficacy for both diabetes and obesity in the clinical setting [9, 10]. Here, GLP1R is linked to obesity disorder.